UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012979
Receipt number R000015127
Scientific Title Study of microRNA using stored serum of subjects in clinical trial of influenza vaccine which was added AdvaxTM
Date of disclosure of the study information 2014/01/28
Last modified on 2016/08/09 15:43:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of microRNA using stored serum of subjects in clinical trial of influenza vaccine which was added AdvaxTM

Acronym

Study of microRNA using stored serum of subjects in clinical trial of influenza vaccine which was added AdvaxTM

Scientific Title

Study of microRNA using stored serum of subjects in clinical trial of influenza vaccine which was added AdvaxTM

Scientific Title:Acronym

Study of microRNA using stored serum of subjects in clinical trial of influenza vaccine which was added AdvaxTM

Region

Japan Australia


Condition

Condition

Influenza

Classification by specialty

Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to search biomarker correlated with the safety and efficacy of AdvaxTM as a new adjuvant ,and to aim elucidation of function of adjuvant and vaccine in vivo.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

MicroRNA expression change in serum is measured by methods such as microRNA chip, a next-generation sequencer and qPCR.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

70 years-old >=

Gender

Male and Female

Key inclusion criteria

subjects whose serum is stored ,who consent to participate in this study

Key exclusion criteria

Not obtained the agreement

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ken Ishii

Organization

National Institutes of Biomedical Innovation,Health and Nutrition

Division name

Laboratory of Adjuvant Innovation

Zip code


Address

7-6-8 Asagi Saito Ibaraki-City Osaka

TEL

072-641-8043

Email

kenishii@biken.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ken Ishii

Organization

National Institutes of Biomedical Innovation,Health and Nutrition

Division name

Laboratory of Adjuvant Innovation

Zip code


Address

7-6-8 Asagi Saito Ibaraki-City Osaka

TEL

072-641-8043

Homepage URL


Email

kenishii@biken.osaka-u.ac.jp


Sponsor or person

Institute

National Institutes of Biomedical Innovation,Health and Nutrition

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Axine Corporation(Australia)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 01 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 07 Month 21 Day

Date of IRB


Anticipated trial start date

2012 Year 10 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

About serum samples
Serum samples are collected from subjects of clinical trial by Vaxine Corporation, and stored.
Then samples and clinical information not containing personal information are only numbered and transported to National Institute of Biomedical Innovation.


Management information

Registered date

2014 Year 01 Month 27 Day

Last modified on

2016 Year 08 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015127


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name